Dyglip-M®

Therapeutic Segment:  Antihyperglycemic

Generic Name: Sitagliptin (as phosphate monohydrate) + Metformin HCl

Indications:
-As initial therapy in patients with type 2 diabetes mellitus to improve glycemic control when diet and exercise do not provide adequate glycemic control.
-As an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus inadequately controlled on Metformin HCl or Sitagliptin alone or in patients already being treated with the combination of Sitagliptin and Metformin HCl.
-In triple combination with a sulphonylurea as an adjunct to diet and exercise in patients with type 2 diabetes mellitus inadequately controlled on their maximal tolera ted dose of Metformin HCl and a sulphonylurea.
-In triple combination with a peroxisome proliferator-activated receptor gamma (PPARγ) agonist (thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of Metformin HCl and a PPARγ agonist.
-In patients with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control in combination with insulin.

Available as                                                               PRESCRIBING INFORMATION